Aspirin might help prevent colorectal cancer, but only if taken for more than 10 years—most people over 70 are not expected to live long enough to see this benefit.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A meta-analysis of long-term RCTs and cohort studies quantifying the time-dependent reduction in colorectal cancer incidence associated with aspirin use in older adults.
A systematic review and meta-analysis of RCTs and prospective cohorts with ≥10 years of follow-up, enrolling adults aged 60–75 at baseline, randomized or stratified by aspirin use (≥10 years vs. <5 years), with primary endpoint of colorectal cancer incidence confirmed by colonoscopy or pathology, analyzed by time-to-event methods.
A prospective cohort study can estimate the association between duration of aspirin use and colorectal cancer incidence in elderly populations.
A prospective cohort study following 8,000 adults aged 65–70 without colorectal cancer, stratified by aspirin use duration (0–5, 6–10, >10 years), with annual colonoscopy screening and cancer diagnosis confirmation over 15 years, adjusting for screening adherence and NSAID use.
A case-control study can compare prior aspirin use duration between elderly individuals diagnosed with colorectal cancer and matched controls.
A matched case-control study comparing 1,200 elderly patients (≥70) diagnosed with colorectal cancer to 2,400 age- and sex-matched controls, assessing aspirin use duration (years) via pharmacy records and structured interviews.
A cross-sectional survey can estimate the prevalence of long-term aspirin use among elderly individuals with and without colorectal cancer history.
A cross-sectional survey of 6,000 adults aged 70+ comparing aspirin use duration (>10 years) between those with prior colorectal cancer diagnosis and those without, using validated questionnaires and medical record verification.
An expert opinion can summarize biological plausibility and timing hypotheses for aspirin’s anticancer effect.
A narrative review by cancer prevention experts summarizing mechanistic and epidemiological evidence on aspirin’s delayed effect on colorectal carcinogenesis.